Development Pipeline
LSO is focusing on a number of cancers for the initial development of Aptocine™: Hepatoma, Metastatic Colorectal Cancer, Prostate Cancer, Pancreatic Cancer, Lung Cancer, Nasopharyngeal Cancer, Head and Neck Cancer, Kidney Cancer, and Glioma/Glioblastoma. Aptocine is also in Phase 2 development for treatment of Benign Prostatic Hyperplasia (BPH), and preclinical development for other non-cancer indications.
Current Clinical Trials
LSO has completed Aptocine treatment in a Phase 3 trial in hepatocellular carcinoma and in a Phase 3 trial in colorectal cancer metastatic to the liver. LSO is also conducting clinical trials in benign prostatic hyperplasia (BPH).
Light Sciences (now LSO) was founded in 1994 to develop a commercially viable light-activated drug product to treat patients with solid tumor cancers. LSO has built a strong development organization with an efficient team overseeing engineering, clinical trials, manufacturing, and regulatory/legal affairs. The company is developing Aptocine, a light-activated drug with a small, single-use, disposable drug activator that is designed for easy use by physicians to provide tolerable, effective, and repeatable treatments to patients.
LSO completed a $67 million Series A preferred financing in late 2005. A $30 million Series B preferred financing was completed in June 2007, and a $40.1 million Series C preferred financing was completed in July 2008.